This symposium is the first of its kind to center the science and voices of LGBTQ+ people on cancer care, community engagement and policies that influence health disparities. Cedars-Sinai Cancer’s mission recognizes that by examining the intersection of sexual orientation, gender and cancer, we can better prevent, detect and cure cancer.
AACI Update | June 2022
Headlines
Registration Now Open for 2022 AACI/CCAF Annual Meeting
Registration is now open for the 2022 AACI/CCAF Annual Meeting, which will take place in person, October 2-4, at InterContinental at the Plaza, Kansas City, MO. This three-day event convenes AACI cancer center members with national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges. Continuing Medical Education (CME) is jointly provided by the American Association for Cancer Research (AACR) and AACI.
Abstract Winners Announced for 14th Annual AACI CRI Meeting
The AACI Clinical Research Innovation (CRI) Steering Committee, with the assistance of peer reviewers from CRI committees, have selected three abstracts from 73 submissions for formal presentation on Wednesday, July 13, at the 14th Annual AACI CRI Meeting. Winning abstract authors represent Sylvester Comprehensive Cancer Center, University of Miami Health System; University of Florida Health Cancer Center; and Mayo Clinic Cancer Center.
Register Today for the 2022 AACI/AACR Hill Day
The 2022 AACI/AACR Hill Day is scheduled for Wednesday, June 15. All faculty and staff of AACI cancer centers and AACR members are invited to spend the day advocating for cancer research funding through virtual meetings. Hill Day registration closes this Friday, June 3.
AACI Condemns Gun Violence in New Statement
AACI's Board of Directors, staff, and cancer center leaders firmly believe that the epidemic of gun violence must be confronted with a sense of urgency – just as we address cancer, COVID-19, and other crises that impact public health. As an association comprised of 104 academic and freestanding cancer centers across the United States and in Canada, AACI is committed to reducing the burden of cancer through research, treatment, and advocacy. In our role as advocates, it is our duty to seek ways to improve health outcomes and quality of life for all people.
Maximize Market Share With Patient Resource
"The Patient Resource guides improve and extend referring provider relationships while providing them confidence in their referral decisions." – Lina Wilson, Physician Relations, The University of Kansas Health System
"Based on this guide alone, if I had a friend with cancer, I’d recommend they come here so they would get this educational piece." – Participant, Patient Focus Group
For more information, contact Amy Galey.
News from the Centers
Neel Elected to National Academy of Sciences
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Benjamin G. Neel, MD, PhD, director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health and an internationally renowned expert in cell signaling and cancer biology, has been elected to the National Academy of Sciences.
Eckhardt Receives Mentorship Award
Livestrong Cancer Institutes, The University of Texas at Austin, Dell Medical School
S. Gail Eckhardt, MD, is the recipient of the 2022 Hologic Inc. Endowed Women Who Conquer Cancer Mentorship Award from the American Society of Clinical Oncology. Dr. Eckhardt, the inaugural director of the Livestrong Cancer Institutes, is being recognized for her outstanding commitment to the professional development of women in oncology.
NSABP Foundation Names Rastogi as CEO
UPMC Hillman Cancer Center
The NSABP (National Surgical Adjuvant Breast and Bowel Project) Foundation has announced that its medical director, Priya Rastogi, MD, will also serve as the chief executive officer of the NSABP effective on July 1, 2022.
Frosch Wins NCCN Foundation Award
Fox Chase Cancer Center, Temple Health
Zachary Frosch, MD, MSHP, a member of the Cancer Prevention and Control research program at Fox Chase Cancer Center, has received a Young Investigator Award from the National Comprehensive Cancer Network and the NCCN Foundation.
Biltibo Receives Career Development Award
Vanderbilt-Ingram Cancer Center
Eden Biltibo, MD, has been selected for the 2022 ASH-CIBMTR-ASTCT Career Development Award. The award is part of the ASH Minority Hematology Fellow Award program, which supports early-career researchers from minority groups historically underrepresented in medicine.
Greenberg Becomes President-Elect of AACR
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Research Center immunologist Philip Greenberg, MD, has begun a year-long term as president-elect of the American Association for Cancer Research (AACR), setting the stage for him to lead the organization as president in 2023.
Two Doctors Named Top Physicians Under 40
Fox Chase Cancer Center, Temple Health
The Pennsylvania Medical Society has announced its 2022 Top Physicians Under 40 award recipients. Two Fox Chase Cancer Center doctors were honored: Kristen Manley, MD, and Jason Castellanos, MD, MS.
Florida Cancer Hospitals Get $100 Million for Research
The UF Health Cancer Center, Sylvester Comprehensive Cancer Center, and Moffitt Cancer Center will receive $100 million for cancer research and treatment in Florida's 2022-2023 spending plan, an increase of about $37 million over the current budget.
$25 Million Commitment to Five Cancer Centers Aims to Reduce Cancer Care Disparities
Georgetown Lombardi Comprehensive Cancer Center
The Ralph Lauren Corporate Foundation will provide $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities in the United States. The funding will benefit Georgetown Lombardi Comprehensive Cancer Center and Memorial Sloan Kettering (MSK) Ralph Lauren Center, as well as three additional locations that will be confirmed.
$11.4 Million Grant Renewed to Further Cancer Research
UK Markey Cancer Center
The University of Kentucky’s Center for Cancer and Metabolism (CCM) will continue its critical mission to research the metabolism of cancer with a renewed Centers of Biomedical Research Excellence grant award from the National Institutes of General Medical Sciences, part of the National Institutes of Health. The grant—totaling $11.4 million—will continue to fund UK’s CCM over the next five years.
Researchers to Examine Obesity Treatment Options With $4.5 Million Grant
The University of Kansas Cancer Center
Population health researcher Christie Befort, PhD, received a $4.5 million grant from the National Cancer Institute to fund her work exploring sustainable obesity treatment options for people in rural communities. Dr. Befort’s project, called RE-TOOL, is a five-year randomized controlled trial involving 16 rural clinics and 560 patients.
Investigators Receive $1.6 Million for Health Equity Research
Montefiore Einstein Comprehensive Cancer Center
Montefiore Einstein Cancer Center has partnered with the Price Family Foundation to fund novel cancer therapies and improving cancer outcomes for historically marginalized communities in the Bronx. The inaugural awards will provide $200,000 in funding over two years to eight teams of basic science, translational, and clinical investigators.
Lopez Named Associate Director for DEI
Sidney Kimmel Cancer Center at Jefferson Health
Sidney Kimmel Cancer Center at Jefferson Health (SKCC) has appointed Ana Maria Lopez, MD, MPH, MACP, FRCP, as associate director for diversity, equity, and inclusion (DEI). The new leadership role will facilitate and coordinate DEI efforts across the SKCC enterprise.
New Chief of Bone Marrow Transplant and Cellular Therapies Named
Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Ira Braunschweig, MD, as chief, Section of Transplant and Cell Therapy at Rutgers Cancer Institute, chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology service line, and director for Cell Therapy and Bone Marrow Transplantation at Robert Wood Johnson University Hospital, an RWJBarnabas facility.
DEI, COE Leadership Appointments Announced
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Marquita Lewis-Thames, PhD; June McKoy, MD, MPH, JD, MBA; Jonathan Moreira, MD; and Adam B. Murphy, MD, MBA, MSCI, have been named to new leadership roles within the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Inaugural Associate Director of DEI Announced
Siteman Cancer Center
Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, announces the appointment of Vetta Sanders Thompson, PhD, as its inaugural associate director of diversity, equity, and inclusion (DEI).
Surgical Oncologist Named Regional Medical Director
Cedars-Sinai Cancer
Pioneering breast cancer surgeon, clinician, and researcher Armando E. Giuliano, MD—who helped introduce sentinel lymph node biopsy in the early 1990s, sparing many women the need for major breast cancer surgery—has been named regional medical director of the Cedars-Sinai Cancer Breast Oncology Program.
New Hematology Chief and Director of the Wesley Center for Immunotherapy Named
Case Comprehensive Cancer Center
Koen van Besien, MD, PhD, will lead the new Wesley Center for Immunotherapy at University Hospitals Seidman Cancer Center as well as the Division of Hematology. He joins UH Seidman Cancer Center from New York-Presbyterian Hospital.
Glenn Named Co-Director of Cancer Research Program
UCLA Jonsson Comprehensive Cancer Center
The UCLA Jonsson Comprehensive Cancer has named Beth Glenn, PhD, co-director of its Cancer Control and Survivorship research program. Dr. Glenn is a professor in the UCLA Fielding School of Public Health and associate director of the UCLA Kaiser Permanente Center for Health Equity. She will join the research program's director, Patricia Ganz, MD, and co-director Roshan Bastani, PhD.
Hassan Joins Breast Cancer Team
UMMC Cancer Center and Research Institute
Masood Muhammad Hassan, MD, has joined the University of Mississippi Medical Center as an assistant professor of pathology. At UMMC, he is a member of the Cancer Center and Research Institute Interdisciplinary Breast Cancer Care team as well as conducting cancer research.
Mayo Announces New Leadership Structure
Mayo Clinic Comprehensive Cancer Center
Three Mayo Clinic Cancer Center leaders have assumed new roles: Stephen M. Ansell, MD, PhD, has been named enterprise deputy director and senior deputy director, Midwest; Roxana Dronca, MD, has been named director, Florida Cancer Programs; and Alan Bryce, MD, will serve as acting director, Arizona Cancer Programs.
Pictured, clockwise from top right: Stephen M. Ansell, MD, PhD; Roxana Dronca, MD; and Alan Bryce, MD
COE Leadership Team Announced
Mayo Clinic Comprehensive Cancer Center
Mayo Clinic Cancer Center has announced a new community outreach and engagement (COE) leadership team to help develop targeted interventions that will lead to sustainable, impactful changes in health equity.
Major Study Links Breast Cancer Treatment With Increased Risk of Cardiovascular Disease
Fred Hutchinson Cancer Center
A new study shows that women receiving certain common therapies for breast cancer may be at increased risk for heart attack, stroke, heart failure, other cardiovascular events, and death.
Immunotherapy Study Offers Hope for Pancreatic Cancer Patients
Sylvester Comprehensive Cancer Center, University of Miami
Researchers at Sylvester Comprehensive Cancer Center in the University of Miami Miller School of Medicine have shown that immunotherapy can be an option for at least one subgroup of pancreatic cancer patients. The study found that patients with inherited BRCA and other similar mutations can achieve complete responses – in some cases going from near death to durable recoveries.
Nanomedicine Targeting Lymph Nodes Key to Triple-Negative Breast Cancer Treatment
University of Michigan Rogel Cancer Center
Research from the University of Michigan Rogel Cancer Center, led by Duxin Sun, PhD, found that targeting the immune microenvironment in lymph nodes and tumors simultaneously led to long-term tumor remission in mice models of metastatic triple negative breast cancer. Further, using nanoparticles to deliver these immune-altering drugs increases treatment efficacy.
Study Illustrates Cost of Cancer Drugs Covered Under Medicare Part D
Vanderbilt-Ingram Cancer Center
A new study highlights how some older Americans diagnosed with cancer can face unlimited out-of-pocket spending for prescription drugs under the current structure of the Medicare Part D benefit. The analysis illustrates how the current design of Medicare’s prescription drug benefit program can cost people without subsidies more than $10,000 for one year of treatment.
Researchers Refining Colorectal Cancer Classification
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Analyzing nearly 500,000 single cells, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are refining how to classify colorectal cancer and identify new targets to develop effective therapies.
Genomic Sequencing is Changing Diagnosis, Treatment for Patients With Brain Cancer
UCSF Helen Diller Family Comprehensive Cancer Center
Patients diagnosed with a type of brain tumor survived for longer when they were treated aggressively with surgery, radiation, and chemotherapy. But far from suggesting that more treatment always leads to better survival, a new UCSF study shows aggressive therapy is best for this deadly tumor masquerading as lower-grade glioma and underscores the critical role of genomic profiling in diagnosing and grading brain tumors.
How Do Patients Feel About Using AI in Health Care?
Yale Cancer Center, Yale School of Medicine
New research from Yale Cancer Center provides a new understanding of patients’ views of artificial intelligence (AI) in health care. While comfort level varied by clinical application, most respondents had positive views about AI’s ability to improve care. Concerns surfaced when potential for misdiagnosis, privacy breaches, reduced time with clinicians, and increased costs were discussed.
Innate Immune Cells and Metastatic Cancer
The Jackson Laboratory Cancer Center
In a new paper, a team led by Karolina Palucka, MD, PhD, and Jan Martinek, PhD, analyzed patient samples of metastatic melanoma for further insight into how cancer cells are able to escape immune response and grow elsewhere in the body.
New Target for CAR T Cells in Solid Tumors Discovered
Moffitt Cancer Center
In a new study, Moffitt Cancer Center researchers share the identification of a new potential target for CAR T cells called OR2H1 that they have demonstrated inhibits growth in lung and ovarian tumors.
UF to Test Novel CAR-Modified T-Cell Technique in Clinical Trial for Glioblastoma
University of Florida Health Cancer Center
University of Florida researchers have received approval from the U.S. Food and Drug Administration to test an investigational new therapy in a first-in-human clinical trial for participants with primary glioblastoma.
Colon Microbes Provide Clues to Favorable Treatment Options in a Subset of Colon Cancer Patients
Rutgers Cancer Institute of New Jersey
Investigators from Rutgers Cancer Institute of New Jersey led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens, including microsatellite-stable and unstable tumors.
New Molecular Subset of Pediatric Liver Cancer Identified
University of Virginia Cancer Center
New research from Baylor College of Medicine and Texas Children’s Cancer Center characterizes a new molecular type of high-risk pediatric liver cancer. The study showed that these tumors have better outcomes when patients were treated by transplantation, rather than by chemotherapy and surgery alone.
Surgical Technique Enables Faster, Fuller Recovery After Radical Prostatectomy
Roswell Park Comprehensive Cancer Center
In a new study, Khurshid Guru, MD, and a team of urologic oncology specialists compared the results of radical prostatectomy between 76 men with prostate cancer who chose hydrodissection RARP compared with 126 men who opted for conventional surgical dissection methods.
Adolescent, Young Adult Leukemia Survivors Have Shorter Life Span Compared to Those Who Have Never Had Cancer
The University of Texas MD Anderson Cancer Center
Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult cancer survivors of acute lymphoblastic leukemia and acute myeloid leukemia have reduced long-term survival rates compared to their peers without cancer. The study also found inferior long-term mortality outcomes persist as far out as three decades into survivorship.
New Approach to Precision Cancer Treatment Identified
Roswell Park Comprehensive Cancer Center
A multidisciplinary team from Roswell Park Comprehensive Cancer Center has uncovered a previously unknown function of a gene that regulates p53, a protein that plays a significant role in more than half of all cancers.
Study Identifies New Molecular Target for Cancer Therapy
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Researchers with OSUCCC – James have identified a new molecular drug target that could result in new cancer drugs with fewer side effects.
'Super Gene' Shows Promise for Preventing Obesity
UK Markey Cancer Center
Nearly three decades after first discovering the tumor-suppressing Par-4 "super gene" that has been shown to kill cancer cells, a team of researchers at UK Markey Cancer Center is now learning about its role in preventing obesity.
E-Cigarette Use Costs U.S. $15 Billion Per Year
UCSF Helen Diller Family Comprehensive Cancer Center
Use of electronic cigarettes costs the United States $15 billion annually in health care expenditures—more than $2,000 per person a year—according to a study by researchers at UCSF. Findings indicate health care costs are $2,000 per year higher among people who vape compared to non-tobacco users. The study is the first to look at the health care costs of e-cigarette use among adults 18 and older.
Polypharmacy is Fraught With Risks, Tricky to Navigate
Wilmot Cancer Institute, UR Medicine
Even for individuals who do not have cancer, multiple medication use is fraught with risks and tricky to navigate because of the emotions involved, according to Erika Ramsdale, MD, a Wilmot Cancer Institute oncologist, geriatrics specialist, and data scientist who led a recent study on polypharmacy.
Early Study Finds New Lymphoma Drug Effective
University of Michigan Rogel Cancer Center
In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma.
Erasing LGBTQ+ Health Care Disparities
Cedars-Sinai Cancer
A first-of-its-kind LGBTQ+ cancer symposium is part of Cedars-Sinai's effort to equalize healthcare access and treatment for all – including patients who identify as LGBTQ+. Studies have shown that the way LGBTQ+ patients are screened, diagnosed, and treated for cancer may put them at a significant disadvantage compared to cisgender heterosexual patients.
Finding the Underlying Mutations Driving CAR T Failure
Sylvester Comprehensive Cancer Center, University of Miami
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and Moffitt Cancer Center have used whole genome sequencing (WGS) to identify mutations that make B-cell lymphomas resistant to CAR T immunotherapies. These findings highlight the importance of WGS to comprehensively map resistance mutations and chromosomal damage.
CAR T Therapy Effective in Black and Hispanic Patients
Montefiore Einstein Comprehensive Cancer Center
In a recent study, investigators at Montefiore Einstein Cancer Center report that Black and Hispanic patients had outcomes and side effects following CAR T treatment that were comparable to their white and Asian counterparts.
Pancreatic Cancer Cells Harness Tissue Turnover to Build Protective Barriers
Laura and Isaac Perlmutter Cancer Center at NYU Langone
In the presence of pancreatic tumors, certain immune cells break down structural proteins into molecules that trigger the building of dense tissue, a known barrier to therapy, a new study finds. Led by researchers from NYU Grossman School of Medicine, the study revolves around the dense protein meshwork that supports organs and helps to rebuild damaged tissue.
Scientists Develop Precision Medicine Approach to Metabolic Therapy for Breast Cancer
Yale Cancer Center, Yale School of Medicine
Scientists at Yale Cancer Center have found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.
Rectal Cancer Disappears After Experimental Use of Immunotherapy
Memorial Sloan Kettering Cancer Center
A small clinical trial conducted by Memorial Sloan Kettering Cancer Center found that every rectal cancer patient who received an experimental immunotherapy treatment had their cancer go into remission.
Hormones Contribute to Sex Disparities in Bladder Cancer, Study Shows
Cedars-Sinai Cancer
Male sex hormones interfere with the body’s ability to fight bladder cancer, likely explaining why males experience higher cancer rates and more deadly disease, according to a new study co-led by a Cedars-Sinai Cancer investigator.
Biomarker in Liquid Biopsy for Lung Cancer Appears More Accurate in Predicting Immunotherapy Response Than Tumor Biopsy
The Tisch Cancer Institute at Mount Sinai
Mount Sinai researchers have validated for the first time that a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy.
Study of Anti-Cancer Mitochondrial Drug Shows Additional Clinical Promise
Stony Brook Cancer Center
A study of the lead agent (CPI-613) in a class of anticancer drugs undergoing U.S. Food and Drug Administration approved clinical trials reveals that CPI-613 is effective against most carcinoma cell lines, and, used in combination, could have efficacy against reducing some tumors. The research was led by Paul M. Bingham, PhD.
Age-Related Lung Changes Provide Pathway for Metastatic Growth of Dormant Melanoma Cancer Cells
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
New laboratory research directed by investigators at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Bloomberg School of Public Health finds that secreted age-induced changes in distant sites such as the lung can effectively reactivate dormant cells and cause them to grow.
Social Stress Factors Drive Cancer Mechanisms That Help Explain Racial Disparities
Duke Cancer Institute, Duke University Medical Center
A Duke Cancer Institute study led by Gayathri Devi, PhD, finds chronic stresses such as racism and poverty alter cellular functions that promote tumor growth and proliferation.
Advanced Radiotherapy is Safe, Effective for Early-Stage Liver Cancer
The Tisch Cancer Institute at Mount Sinai
Researchers at the Icahn School of Medicine at Mount Sinai found that an advanced radiotherapy technique called radiation segmentectomy may be effective against very early to early-stage hepatocellular carcinoma (HCC). It is the first prospective study to explore the efficacy and outcomes of this technique. Results suggest it may be a curative treatment for inoperable, early-stage HCC.
Study Uncovers New Treatment Approaches for Liver Cancer Patients
Cedars-Sinai Cancer
Experts from Cedars-Sinai Cancer have analyzed patient samples, along with studies conducted in animal models, to identify a novel immune checkpoint pathway to treat hepatocellular carcinoma. The findings are centered on the discovery of a novel role for the IL-27 signaling pathway in liver cancer.
New AACI Mailing Address
Association of American Cancer Institutes
Effectively immediately, all mail for AACI should be directed to:
Association of American Cancer Institutes
PO Box 7317
Pittsburgh, PA 15213
Upon His Retirement, Modrich Reflects on Career
Duke Cancer Institute, Duke University Medical Center
Paul Modrich, PhD, James B. Duke Professor of Biochemistry, professor of chemistry, and member of Duke Cancer Institute, came to Duke in 1976 – when Durham had a small-town feel, the smell of curing tobacco filled the air, and southern accents were the norm.
IT Innovations Capture National Attention
Wilmot Cancer Institute, UR Medicine
Eric Snyder, director of informatics at the Wilmot Cancer Institute, wants to change the nation’s thinking around information technology in health care. Snyder made headway recently when the biggest professional organization in the field invited him to make three presentations at the Healthcare Information and Management Systems Society 2022 annual meeting.
Partnership to Create First Focused Ultrasound Cancer Immunotherapy Center
University of Virginia Cancer Center
UVA Health and the Charlottesville-based Focused Ultrasound Foundation have announced the launch of the Focused Ultrasound Cancer Immunotherapy Center, the world’s first center dedicated specifically to advancing a focused ultrasound and cancer immunotherapy treatment approach that could revolutionize 21st-century cancer care.
Study Found Large Segment of Arkansans Still Susceptible to COVID-19 in Late 2020, 2021
UAMS Winthrop P. Rockefeller Cancer Institute
A team of scientists at the University of Arkansas for Medical Sciences (UAMS) carried out an eight-month seroprevalence survey that found 85 percent of the state’s population was still susceptible to the virus in late 2020.
COVID-19 Vaccine Effective in People Receiving Cancer Treatment, Study Finds
The University of Kansas Cancer Center
People undergoing active cancer treatment, including stem cell transplant, should receive the COVID-19 vaccine, according to a new study. People with cancer are at a higher risk of developing severe COVID-19 and dying from it. These findings provide guidance to a group largely excluded from clinical trials evaluating the efficacy of COVID-19 vaccines. Qamar Khan, MD, led the study.
Researchers Find Links Between Sociodemographic Factors, COVID-19 Preventive Efforts
UAMS Winthrop P. Rockefeller Cancer Institute
Researchers at the University of Arkansas for Medical Sciences (UAMS) Office of Community Health & Research have found that Black Arkansans who reported racial discrimination in the criminal justice system also experienced higher levels of hesitancy toward COVID-19 vaccines.
Cancer Research Building Construction Begins
Sylvester Comprehensive Cancer Center, University of Miami
Sylvester Comprehensive Cancer Center is celebrating the groundbreaking for a 244,000-square-foot, state-of-the-art Sylvester Comprehensive Cancer Center - Transformational Cancer Research Building. The 12-story facility is slated to open in 2024.
Expanding Commitment to Advance Cancer Research in the Mountain West
Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute at the University of Utah announces a formal expansion of its catchment area. In addition to Utah, it now includes Idaho, Montana, Nevada, and Wyoming. Neli Ulrich, PhD, MS, is the center's executive director.
Cancer Center Jobs
No items found.
Meeting Announcements
LGBTQ+ Cancer Symposium
June 2, 2022
AACI/AACR Virtual Hill Day
June 15, 2022
Save the date for the 2022 AACI/AACR Virtual Hill Day. More details to come.
14th Annual AACI CRI Meeting
July 12, 2022
The AACI Clinical Research Innovation (CRI) program serves as a network for research leaders to develop and share best practices for the efficient operation of clinical trials offices (CTO) at AACI cancer centers. The programming of the 14th Annual AACI CRI Meeting, “Partnering in Progress,” aligns with CRI's strategic goal of stimulating cancer center interactions to maximize resources by creating opportunities for peer-to-peer networking and collaboration.
The health and safety of meeting attendees is of paramount importance. AACI continues to closely monitor the COVID-19 pandemic and related public health guidelines. We are currently planning for an in-person event and will implement protective measures in accordance with current guidelines from the Centers for Disease Control and Prevention (CDC) and the City of Chicago. A virtual option is available to those unable to attend in person.
Please visit the meeting website for more information on COVID-19 masking, vaccination, and testing policies:
Health and Safety Measures
FAQ
AACI reserves the right to revise vaccination, masking, and testing policies based on evolving public health recommendations, and will notify attendees of any changes as soon as possible.
31st Annual Short Course on Experimental Models of Human Cancer
August 14, 2022
Unlike graduate courses or an academic seminar series that can span a full year or more, the 31st annual JAX Cancer Short Course provides highly relevant, cutting-edge material in just 10 days. This intensive course combines seminars and workshop-based learning opportunities from leaders in cancer genetics, cancer cell biology, emerging animal models of human cancers, cancer immunology & therapy, and computational science.
The JAX Short Course ia a hybrid event. The virtual option will be presented through a combination of on-demand lectures, live panel discussions, virtual workshops and Q&A sessions. Live sessions will be recorded and posted on a centralized canvas course for participants within 72 hours of airing.
For more information, please contact Lothar Holzke.
The JAX Short Course ia a hybrid event. The virtual option will be presented through a combination of on-demand lectures, live panel discussions, virtual workshops and Q&A sessions. Live sessions will be recorded and posted on a centralized canvas course for participants within 72 hours of airing.
For more information, please contact Lothar Holzke.
2022 AACI/CCAF Annual Meeting
October 2, 2022
AACI cancer centers form North America's cancer research infrastructure and are hubs of critical discoveries, treatment advances and improvements in patient care. AACI and the Cancer Center Administrators Forum (CCAF) jointly formulated the program for the 2022 AACI/CCAF Annual Meeting.
This three-day event convenes AACI cancer center members with national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges. No other program presents information on cancer research and patient care issues as they pertain to the leaders of the nation's cancer centers and provides those leaders with a forum to discuss common issues with their peers.
Continuing Medical Education (CME) is jointly provided by the American Association for Cancer Research (AACR) and AACI. Your participation in this national meeting helps us chart a course for AACI's work on behalf of its cancer center network. We look forward to hosting you and your colleagues for this always innovative and high-quality educational experience.